多西他赛与奈达铂联合治疗晚期非小细胞肺癌的效果分析

Efficacy of Docetaxel Combined with Nedaplatin in Treatment of Advanced Non-small Cell Lung Cancer

目的:研究多西他赛与奈达铂联合治疗晚期非小细胞肺癌的作用。方法:选择2015年1月-2017年12月笔者所在医院收治的130例晚期非小细胞肺癌患者作为研究对象,随机均分为对照组与观察组,每组65例。两组均根据自身情况实施抗过敏治疗及止吐治疗,对照组于此基础上给予多西他赛治疗,观察组于多西他赛治疗基础上联合奈达铂治疗。比较两组平均生存时间、治疗效果、并发症发生情况。结果:观察组治疗总有效率为95.38%,高于对照组的72.31%,且观察组生存平均时间长于对照组,观察组并发症发生率为3.08%,低于对照组的29.23%,两组差异均有统计学意义(P<0.05)。结论:多西他赛联合奈达铂是一种科学有效的治疗方案,对晚期非小细胞肺癌控制病情、延长寿命具有重要意义。

Objective:To study the effect of Docetaxel combined with Nedaplatin in the treatment of advanced non-small cell lung cancer.Method:A total of 130 patients with advanced non-small cell lung cancer admitted to the hospital from January 2015 to December 2017 were randomly divided into control group and observation group,with 65 cases in each group.Both groups were treated with anti-allergic treatment and antiemetic treatment according to their own conditions.The control group was given Docetaxel on this basis,and the observation group was treated with Nedaplatin on the basis of docetaxel treatment.The average survival time,treatment effect,and complications of the two groups were compared.Result:After treatment,the effective rate of the observation group was 95.38%,which was much higher than 72.31% of the control group.The average survival time of the observation group was longer than that of the control group.The incidence of complications in the observation group was 3.08%,which was lower than 29.23% of the control group.There were significant differences between the two groups(P<0.05).Conclusion:Docetaxel combined with Nedaplatin is a scientific and effective treatment for advanced non-small cell lung cancer.It is of great significance to control the disease and prolong the life span of advanced non-small cell lung cancer.